FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Kristoffer Hellstrand

Research Profile

Anatomy

Chemicals & Drugs

Living Beings

Hepacivirus

Physiology

Disorders

Hepatitis C, Chronic

Procedures

Immunotherapy

Concepts & Ideas

Co-author Network

Publications

TOP 3
Magnus Lindh; S Nilsson; B Arnholm; Per Björkman; Kristoffer Hellstrand; Martin Lagging; T Wahlberg; E Wallmark; Ola Weiland; Rune Wejstål; Johan Westin; Anders Widell; Gunnar Norkrans
Dynamic tailoring of treatment durations improves efficiency of hepatitis C treatment with pegylated interferon and ribavirin.
Jonas Söderholm; Jesper Waldenström; Rune Wejstål; Johan Westin; Stefan Zeuzem; Galia Askarieh; Pierre-Yves Bochud; Carlo Ferrari; Bart L Haagmans; Kristoffer Hellstrand; Magnus Lindh; Gabriele Missale; Francesco Negro; Avidan U Neumann; Gunnar Norkrans; Jean-Michel Pawlotsky; Massimo Pilli; Martin Lagging
Impact of soluble CD26 on treatment outcome and hepatitis C virus-specific T cells in chronic hepatitis C virus genotype 1 infection.
Johan Aurelius; Mats Brune; Kristoffer Hellstrand; Anna Martner; Lars Palmqvist; Rebecca E Riise; Ana I Romero; Fredrik B Thorén
Chronic myeloid leukemic cells trigger poly(ADP-ribose) polymerase-dependent inactivation and cell death in lymphocytes.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Kristoffer Hellstrand (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2013: Magnus Lindh; S Nilsson; B Arnholm; Per Björkman; Kristoffer Hellstrand; Martin Lagging; T Wahlberg; E Wallmark; Ola Weiland; Rune Wejstål; Johan Westin; Anders Widell; Gunnar Norkrans
Dynamic tailoring of treatment durations improves efficiency of hepatitis C treatment with pegylated interferon and ribavirin.
Journal of viral hepatitis 2013;20(4):e82-9.
2013: Jonas Söderholm; Jesper Waldenström; Rune Wejstål; Johan Westin; Stefan Zeuzem; Galia Askarieh; Pierre-Yves Bochud; Carlo Ferrari; Bart L Haagmans; Kristoffer Hellstrand; Magnus Lindh; Gabriele Missale; Francesco Negro; Avidan U Neumann; Gunnar Norkrans; Jean-Michel Pawlotsky; Massimo Pilli; Martin Lagging
Impact of soluble CD26 on treatment outcome and hepatitis C virus-specific T cells in chronic hepatitis C virus genotype 1 infection.
PloS one 2013;8(2):e56991.
2013: Johan Aurelius; Mats Brune; Kristoffer Hellstrand; Anna Martner; Lars Palmqvist; Rebecca E Riise; Ana I Romero; Fredrik B Thorén
Chronic myeloid leukemic cells trigger poly(ADP-ribose) polymerase-dependent inactivation and cell death in lymphocytes.
Journal of leukocyte biology 2013;93(1):155-60.
2012: Johan Aurelius; Mats Brune; Markus Hansson; Kristoffer Hellstrand; Anna Martner; Lars Palmqvist; Fredrik B Thoren
Remission maintenance in acute myeloid leukemia: impact of functional histamine H2 receptors expressed by leukemic cells.
Haematologica 2012;97(12):1904-8.
2012: N Mossberg; Charlotta Movitz; S Nilsson; M Nordin; B Andersson; Tomas Bergström; Kristoffer Hellstrand; Oluf Andersen
The recurrent Guillain-Barré syndrome: a long-term population-based study.
Acta neurologica Scandinavica 2012;126(3):154-61.
2012: Johan Aurelius; Mats Brune; Markus Hansson; Kristoffer Hellstrand; Lars Palmqvist; Fredrik B Thorén; Ali A Akhiani; Anna Martner
Monocytic AML cells inactivate antileukemic lymphocytes: role of NADPH oxidase/gp91(phox) expression and the PARP-1/PAR pathway of apoptosis.
Blood 2012;119(24):5832-7.
2012: Karolina Rembeck; Stefano Romeo; Johan Westin; Mads Rauning Buhl; Maria Antonella Burza; Peer Brehm Christensen; Martti Färkkilä; Kristoffer Hellstrand; Martin Lagging; Nina Langeland; Magnus Lindh; Cristina Maglio; Kristine Mørch; Gunnar Norkrans; Court Pedersen; Carlo Pirazzi
PNPLA 3 I148M genetic variant associates with insulin resistance and baseline viral load in HCV genotype 2 but not in genotype 3 infection.
BMC medical genetics 2012;13():82.
2012: Åsa Alsiö; Mads Rauning Buhl; Galia Askarieh; Peer Brehm Christensen; Martti Färkkilä; Bart L Haagmans; Kristoffer Hellstrand; Nina Langeland; Kristine Mørch; Salmir Nasic; Gunnar Norkrans; Court Pedersen; Karolina Rembeck; Johan Westin; Martin Lagging
Impact of obesity on the bioavailability of peginterferon-α2a and ribavirin and treatment outcome for chronic hepatitis C genotype 2 or 3.
PloS one 2012;7(5):e37521.
2012: Karolina Rembeck; Johan Westin; Asa Alsiö; Mads Rauning Buhl; Peer Brehm Christensen; Martti Färkkilä; Kristoffer Hellstrand; Nina Langeland; Magnus Lindh; Kristine Mørch; Gunnar Norkrans; Court Pedersen; Martin Lagging
Impact of IL28B-related single nucleotide polymorphisms on liver histopathology in chronic hepatitis C genotype 2 and 3.
PloS one 2012;7(1):e29370.
2011: P-Y Bochud; Carlo Ferrari; Bart L Haagmans; Kristoffer Hellstrand; Gabriele Missale; Francesco Negro; Avidan U Neumann; Jean-Michel Pawlotsky; S Schalm; A Soulier; Stefan Zeuzem; Stephanie Bibert; Martin Lagging
IL28B polymorphisms predict reduction of HCV RNA from the first day of therapy in chronic hepatitis C.
Journal of hepatology 2011;55(5):980-8.
2011: Magnus Lindh; S Nilsson; Gunnar Norkrans; J Söderholm; T Wahlberg; Rune Wejstål; Johan Westin; B Arnholm; A Eilard; Martin Lagging; Kristoffer Hellstrand
IL28B polymorphisms determine early viral kinetics and treatment outcome in patients receiving peginterferon/ribavirin for chronic hepatitis C genotype 1.
Journal of viral hepatitis 2011;18(7):e325-31.
2011: Magdalena Ydreborg; Petter Malmström; Ann Söderström; Johan Westin; Asa Alsiö; Birgitta Arnholm; Agneta Håkanson; Kristoffer Hellstrand; Martin Lagging
Look-back screening for the identification of transfusion-induced hepatitis C virus infection in Sweden.
Scandinavian journal of infectious diseases 2011;43(6-7):522-7.
2011: Magnus Lindh; Martin Lagging; Martti Färkkilä; Nina Langeland; Kristine Mørch; Staffan Nilsson; Gunnar Norkrans; Court Pedersen; Mads Rauning Buhl; Johan Westin; Kristoffer Hellstrand
Interleukin 28B gene variation at rs12979860 determines early viral kinetics during treatment in patients carrying genotypes 2 or 3 of hepatitis C virus.
The Journal of infectious diseases 2011;203(12):1748-52.
2011: Magnus Lindh; K Mørch; S Nilsson; B Arnholm; M R Buhl; A Eilard; M Färkkilä; Kristoffer Hellstrand; Martin Lagging; Nina Langeland; Court Pedersen; T Wahlberg; Rune Wejstål; Johan Westin; Gunnar Norkrans
Hepatitis C treatment response kinetics and impact of baseline predictors.
Journal of viral hepatitis 2011;18(6):400-7.
2011: Martin Lagging; Sa Alsiö; Kristoffer Hellstrand; Gunnar Norkrans
Is HCV RNA analysis at day 7 cost-effective in deciding the duration of therapy in chronic HCV genotype 2/3 infection?
Journal of hepatology 2011;54(4):835-6; author reply 836-7.
2011: Martin Lagging; Asa Alsiö; Nina Langeland; Court Pedersen; Martti Färkkilä; Mads Rauning Buhl; Kristine Mørch; Kristoffer Hellstrand; Gunnar Norkrans
Early determination of hepatitis C virus RNA may help to decide the duration of therapy for chronic hepatitis C virus genotype 2/3 infection.
Hepatology (Baltimore, Md.) 2011;53(3):1067-8.
2011: Johan Westin; Kristoffer Hellstrand; Amar P Dhillon; Martin Lagging
Are FoxP3(+) cells involved in hyporesponsiveness to interferon/ribavirin therapy in chronic hepatitis C?
Journal of viral hepatitis 2011;18(2):149-51.
2011: Martin Lagging; Galia Askarieh; Francesco Negro; Stephanie Bibert; Jonas Söderholm; Johan Westin; Magnus Lindh; Ana Romero; Gabriele Missale; Carlo Ferrari; Avidan U Neumann; Jean-Michel Pawlotsky; Bart L Haagmans; Stefan Zeuzem; Pierre-Yves Bochud; Kristoffer Hellstrand
Response prediction in chronic hepatitis C by assessment of IP-10 and IL28B-related single nucleotide polymorphisms.
PloS one 2011;6(2):e17232.
2010: Charlotta Movitz; Tomas Bergström; Kristian Borg; Kristoffer Hellstrand; Erik Lycke; Jan Lycke
Leukocyte myeloperoxidase and pathogenesis of the post-polio syndrome.
Scandinavian journal of infectious diseases 2010;42(11-12):958-60.
2010: Magnus Lindh; Martin Lagging; Gunnar Norkrans; Kristoffer Hellstrand
Observed and calculated interleukin-28B genotype frequencies in hepatitis C virus infection.
Hepatology (Baltimore, Md.) 2010;52(5):1860-1; author reply 1861-2.
2010: Anna Martner; Fredrik B Thorén; Johan Aurelius; Jonas Söderholm; Mats Brune; Kristoffer Hellstrand
Immunotherapy with histamine dihydrochloride for the prevention of relapse in acute myeloid leukemia.
Expert review of hematology 2010;3(4):381-91.
2010: Charlotta Movitz; Lars Brive; Kristoffer Hellstrand; Marie-Josèphe Rabiet; Claes Dahlgren
The annexin I sequence gln(9)-ala(10)-trp(11)-phe(12) is a core structure for interaction with the formyl peptide receptor 1.
The Journal of biological chemistry 2010;285(19):14338-45.
2010: Galia Askarieh; Asa Alsiö; Paolo Pugnale; Francesco Negro; Carlo Ferrari; Avidan U Neumann; Jean-Michel Pawlotsky; Solko W Schalm; Stefan Zeuzem; Gunnar Norkrans; Johan Westin; Jonas Söderholm; Kristoffer Hellstrand; Martin Lagging
Systemic and intrahepatic interferon-gamma-inducible protein 10 kDa predicts the first-phase decline in hepatitis C virus RNA and overall viral response to therapy in chronic hepatitis C.
Hepatology (Baltimore, Md.) 2010;51(5):1523-30.
2010: Asa Alsiö; Peer Brehm Christensen; Martti Färkkilä; Nina Langeland; Mads Rauning Buhl; Court Pedersen; Kristine Mørch; Bart L Haagmans; Johan Westin; Kristoffer Hellstrand; Gunnar Norkrans; Martin Lagging
Nonresponder patients with hepatitis C virus genotype 2/3 infection: a question of low systemic interferon concentrations?
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2010;50(4):e22-5.
2010: Natalia Mossberg; Oluf Andersen; Magnus Nordin; Staffan Nilsson; Ake Svedhem; Tomas Bergström; Kristoffer Hellstrand; Charlotta Movitz
Leukocyte oxygen radical production determines disease severity in the recurrent Guillain-Barré syndrome.
Journal of inflammation (London, England) 2010;7():40.
2009: Ana I Romero; Fredrik B Thorén; J Aurelius; G Askarieh; Mats Brune; Kristoffer Hellstrand
Post-consolidation immunotherapy with histamine dihydrochloride and interleukin-2 in AML.
Scandinavian journal of immunology 2009;70(3):194-205.
2009: Fredrik B Thorén; Ana I Romero; Mats Brune; Kristoffer Hellstrand
Histamine dihydrochloride and low-dose interleukin-2 as post-consolidation immunotherapy in acute myeloid leukemia.
Expert opinion on biological therapy 2009;9(9):1217-23.
2009: Natalia Mossberg; Charlotta Movitz; Kristoffer Hellstrand; Tomas Bergström; Staffan Nilsson; Oluf Andersen
Oxygen radical production in leukocytes and disease severity in multiple sclerosis.
Journal of neuroimmunology 2009;213(1-2):131-4.
2009: Mats Brune; Ana I Romero; Kristoffer Hellstrand
Histamine dihydrochloride and interleukin-2 in acute myeloid leukemia--background and results.
Inflammation research : official journal of the European Histamine Research Society ... [et al.] 2009;58 Suppl 1():4-8.
2008: Martin Lagging; Nina Langeland; Court Pedersen; Martti Färkkilä; Mads Rauning Buhl; Kristine Mørch; Amar P Dhillon; Asa Alsiö; Kristoffer Hellstrand; Johan Westin; Peer Christensen; Peter Leutscher; Gunnar Norkrans
Weight-adjusted dosing of ribavirin and importance of hepatitis C virus RNA below 1000 IU/mL by day 7 in short-term peginterferon therapy for chronic genotype 2/3 hepatitis C virus infection.
Hepatology (Baltimore, Md.) 2008;48(2):695.
2008: Martin Lagging; Nina Langeland; Court Pedersen; Martti Färkkilä; Mads Rauning Buhl; Kristine Mørch; Amar P Dhillon; Asa Alsiö; Kristoffer Hellstrand; Johan Westin; Gunnar Norkrans
Randomized comparison of 12 or 24 weeks of peginterferon alpha-2a and ribavirin in chronic hepatitis C virus genotype 2/3 infection.
Hepatology (Baltimore, Md.) 2008;47(6):1837-45.
2008: Maria Dahlberg; Claes Dahlgren; Kristoffer Hellstrand; Charlotta Movitz
A new chemiluminescence paradox: selective inhibition of isoluminol-amplified activity in phagocytes by peptides from annexin AI.
Luminescence : the journal of biological and chemical luminescence 2008;23(3):139-43.
2008: M Lindh; Kristoffer Hellstrand; Gunnar Norkrans
Wider indications for treatment of chronic hepatitis B?
Journal of viral hepatitis 2008;15(3):237.
2008: Johan Westin; Magdalena Ydreborg; Sara Islam; Asa Alsiö; Amar P Dhillon; Jean-Michel Pawlotsky; Stefan Zeuzem; Solko W Schalm; Carlo Ferrari; Avidan U Neumann; Kristoffer Hellstrand; Martin Lagging
A non-invasive fibrosis score predicts treatment outcome in chronic hepatitis C virus infection.
Scandinavian journal of gastroenterology 2008;43(1):73-80.
2007: Natalia Mossberg; Oluf Andersen; Staffan Nilsson; Claes Dahlgren; Kristoffer Hellstrand; Magnus Lindh; Ake Svedhem; Tomas Bergström; Charlotta Movitz
Oxygen radical production and severity of the Guillain--Barré syndrome.
Journal of neuroimmunology 2007;192(1-2):186-91.
2007: Mark R Middleton; A Hauschild; D Thomson; R Anderson; S Burdette-Radoux; Kurt Gehlsen; Kristoffer Hellstrand; Peter Naredi
Results of a multicenter randomized study to evaluate the safety and efficacy of combined immunotherapy with interleukin-2, interferon-{alpha}2b and histamine dihydrochloride versus dacarbazine in patients with stage IV melanoma.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2007;18(10):1691-7.
2007: Magnus Lindh; Erik Alestig; Birgitta Arnholm; Anders Eilard; Kristoffer Hellstrand; Martin Lagging; Thomas Wahlberg; Rune Wejstål; Johan Westin; Gunnar Norkrans
Response prediction and treatment tailoring for chronic hepatitis C virus genotype 1 infection.
Journal of clinical microbiology 2007;45(8):2439-45.
2007: Fredrik B Thorén; Ana I Romero; Svante Hermodsson; Kristoffer Hellstrand
The CD16-/CD56bright subset of NK cells is resistant to oxidant-induced cell death.
Journal of immunology (Baltimore, Md. : 1950) 2007;179(2):781-5.
2007: Fredrik B Thorén; Asa Betten; Ana I Romero; Kristoffer Hellstrand
Cutting edge: Antioxidative properties of myeloid dendritic cells: protection of T cells and NK cells from oxygen radical-induced inactivation and apoptosis.
Journal of immunology (Baltimore, Md. : 1950) 2007;179(1):21-5.
2007: Johan Westin; Kristoffer Hellstrand; Asa Alsiö; Magdalena Ydreborg; Carlo Ferrari; Avidan U Neumann; Jean-Michel Pawlotsky; Solko W Schalm; Stefan Zeuzem; Elke Verhey-Hart; Martin Lagging
Impact of disease severity on outcome of antiviral therapy in treatment-naïve patients with chronic hepatitis C.
Hepatology (Baltimore, Md.) 2007;45(5):1333-4; author reply 1334.
2007: Johan Westin; Martin Lagging; Amar P Dhillon; Gunnar Norkrans; Ana I Romero; Jean-Michel Pawlotsky; Stefan Zeuzem; Solko W Schalm; Elke Verheij-Hart; Francesco Negro; Gabriele Missale; Avidan U Neumann; Kristoffer Hellstrand
Impact of hepatic steatosis on viral kinetics and treatment outcome during antiviral treatment of chronic HCV infection.
Journal of viral hepatitis 2007;14(1):29-35.
2007: Esther Lukasiewicz; Kristoffer Hellstrand; Johan Westin; Carlo Ferrari; Avidan U Neumann; Jean-Michel Pawlotsky; Solko W Schalm; Stefan Zeuzem; Bart J Veldt; Bettina E Hansen; Elke Verhey-Hart; Martin Lagging
Predicting treatment outcome following 24 weeks peginterferon alpha-2a/ribavirin therapy in patients infected with HCV genotype 1: utility of HCV-RNA at day 0, day 22, day 29, and week 6.
Hepatology (Baltimore, Md.) 2007;45(1):258-9.
2006: Martin Lagging; Ana I Romero; Johan Westin; Gunnar Norkrans; Amar P Dhillon; Jean-Michel Pawlotsky; Stefan Zeuzem; Michael von Wagner; Francesco Negro; Solko W Schalm; Bart L Haagmans; Carlo Ferrari; Gabriele Missale; Avidan U Neumann; Elke Verheij-Hart; Kristoffer Hellstrand
IP-10 predicts viral response and therapeutic outcome in difficult-to-treat patients with HCV genotype 1 infection.
Hepatology (Baltimore, Md.) 2006;44(6):1617-25.
2006: Ana I Romero; Martin Lagging; Johan Westin; Amar P Dhillon; Lynn B Dustin; Jean-Michel Pawlotsky; Avidan U Neumann; Carlo Ferrari; Gabriele Missale; Bart L Haagmans; Solko W Schalm; Stefan Zeuzem; Francesco Negro; Elke Verheij-Hart; Kristoffer Hellstrand
Interferon (IFN)-gamma-inducible protein-10: association with histological results, viral kinetics, and outcome during treatment with pegylated IFN-alpha 2a and ribavirin for chronic hepatitis C virus infection.
The Journal of infectious diseases 2006;194(7):895-903.
2006: Mats Brune; Sylvie Castaigne; John Catalano; Kurt Gehlsen; Anthony Ho; Wolf-Karsten Hofmann; Donna E Hogge; Bo Nilsson; Reuven Or; Ana I Romero; Jacob M Rowe; Bengt Simonsson; Ruth Spearing; Edward A Stadtmauer; Jeff Szer; Elisabeth Wallhult; Kristoffer Hellstrand
Improved leukemia-free survival after postconsolidation immunotherapy with histamine dihydrochloride and interleukin-2 in acute myeloid leukemia: results of a randomized phase 3 trial.
Blood 2006;108(1):88-96.
2006: Fredrik B Thorén; Ana I Romero; Kristoffer Hellstrand
Oxygen radicals induce poly(ADP-ribose) polymerase-dependent cell death in cytotoxic lymphocytes.
Journal of immunology (Baltimore, Md. : 1950) 2006;176(12):7301-7.
2006: Ana I Romero; Fredrik B Thorén; Mats Brune; Kristoffer Hellstrand
NKp46 and NKG2D receptor expression in NK cells with CD56dim and CD56bright phenotype: regulation by histamine and reactive oxygen species.
British journal of haematology 2006;132(1):91-8.
2005: Jennie Karlsson; Huamei Fu; François Boulay; Claes Dahlgren; Kristoffer Hellstrand; Charlotta Movitz
Neutrophil NADPH-oxidase activation by an annexin AI peptide is transduced by the formyl peptide receptor (FPR), whereas an inhibitory signal is generated independently of the FPR family receptors.
Journal of leukocyte biology 2005;78(3):762-71.
2005: Anne Marie Asemissen; Carmen Scheibenbogen; Anne Letsch; Kristoffer Hellstrand; Fredrik B Thorén; Kurt Gehlsen; Alexander Schmittel; Eckhard Thiel; Ulrich Keilholz
Addition of histamine to interleukin 2 treatment augments type 1 T-cell responses in patients with melanoma in vivo: immunologic results from a randomized clinical trial of interleukin 2 with or without histamine (MP 104).
Clinical cancer research : an official journal of the American Association for Cancer Research 2005;11(1):290-7.
2004: Fredrik B Thorén; Ana Romero; Magnus Lindh; Claes Dahlgren; Kristoffer Hellstrand
A hepatitis C virus-encoded, nonstructural protein (NS3) triggers dysfunction and apoptosis in lymphocytes: role of NADPH oxidase-derived oxygen radicals.
Journal of leukocyte biology 2004;76(6):1180-6.
2004: Markus Hansson; Ana Romero; Fredrik B Thorén; Svante Hermodsson; Kristoffer Hellstrand
Activation of cytotoxic lymphocytes by interferon-alpha: role of oxygen radical-producing mononuclear phagocytes.
Journal of leukocyte biology 2004;76(6):1207-13.
2004: Sanjiv S Agarwala; Kristoffer Hellstrand; Kurt Gehlsen; Peter Naredi
Immunotherapy with histamine and interleukin 2 in malignant melanoma with liver metastasis.
Cancer immunology, immunotherapy : CII 2004;53(9):840-1.
2004: Asa Betten; Claes Dahlgren; Ulf-Henrik Mellqvist; Svante Hermodsson; Kristoffer Hellstrand
Oxygen radical-induced natural killer cell dysfunction: role of myeloperoxidase and regulation by serotonin.
Journal of leukocyte biology 2004;75(6):1111-5.
2004: Johan Bylund; Sara Pellmé; Huamei Fu; Ulf-Henrik Mellqvist; Kristoffer Hellstrand; Anna Karlsson; Claes Dahlgren
Cytochalasin B triggers a novel pertussis toxin sensitive pathway in TNF-alpha primed neutrophils.
BMC cell biology 2004;5():21.
2004: Per Lindnér; Magnus Rizell; Jan Mattsson; Kristoffer Hellstrand; Peter Naredi
Combined treatment with histamine dihydrochloride, interleukin-2 and interferon-alpha in patients with metastatic melanoma.
Anticancer research 2004;24(3b):1837-42.
2003: Asa Betten; Claes Dahlgren; Svante Hermodsson; Kristoffer Hellstrand
Histamine inhibits neutrophil NADPH oxidase activity triggered by the lipoxin A4 receptor-specific peptide agonist Trp-Lys-Tyr-Met-Val-Met.
Scandinavian journal of immunology 2003;58(3):321-6.
2003: Kristoffer Hellstrand
Melanoma immunotherapy: a battle against radicals?
Trends in immunology 2003;24(5):232-3; author reply 234.
2003: Andreas Schjellerup Jørkov; Frede Donskov; Torben Steiniche; Annika Ternesten-Bratel; Peter Naredi; Kristoffer Hellstrand; Marianne Hokland
Immune response in blood and tumour tissue in patients with metastatic malignant melanoma treated with IL-2, IFN alpha and histamine dihydrochloride.
Anticancer research 2003;23(1B):537-42.
2002: Maria Bokarewa; Kristoffer Hellstrand; Andrej Tarkowski
Phosphorotioated oligonucleotides trigger synthesis of human coagulation serine proteases.
Thrombosis and haemostasis 2002;88(5):788-93.
2002: Yoav Lurie; Frederik Nevens; Z G Aprosina; T A Fedorova; A V Kalinin; E A Klimova; Y Ilan; M V Maevskaya; T W Warnes; N D Yuschuk; Kristoffer Hellstrand; Kurt Gehlsen
A multicentre, randomized study to evaluate the safety and efficacy of histamine dihydrochloride and interferon-alpha-2b for the treatment of chronic hepatitis C.
Journal of viral hepatitis 2002;9(5):346-53.
2002: Sanjiv S Agarwala; Kristoffer Hellstrand; Peter Naredi
Interleukin-2 and histamine dihydrochloride in metastatic melanoma.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2002;20(16):3558-9.
2002: Magnus Rizell; Kristoffer Hellstrand; Per Lindnér; Peter Naredi
Monotherapy with histamine dihydrochloride suppresses in vivo growth of a rat sarcoma in liver and subcutis.
Anticancer research 2002;22(4):1943-8.
2002: Kristoffer Hellstrand
Histamine in cancer immunotherapy: a preclinical background.
Seminars in oncology 2002;29(3 Suppl 7):35-40.
2002: Frede Donskov; Hans von der Maase; R Henriksson; U Stiemer; P Wersäll; Hanne Nellemann; Kristoffer Hellstrand; K Engman; Peter Naredi
Outpatient treatment with subcutaneous histamine dihydrochloride in combination with interleukin-2 and interferon-alpha in patients with metastatic renal cell carcinoma: results of an open single-armed multicentre phase II study.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2002;13(3):441-9.
2002: Magnus Rizell; Peter Naredi; Per Lindnér; Kristoffer Hellstrand; Mark Sarno; Per-Anders Jansson
Histamine pharmacokinetics in tumor and host tissues after bolus-dose administration in the rat.
Life sciences 2002;70(8):969-76.
2002: Sanjiv S Agarwala; John Glaspy; Steven J O'Day; Malcolm Mitchell; John C Gutheil; Eric Whitman; Rene Gonzalez; Evan M Hersh; Lynn Feun; Robert Belt; Frank Meyskens; Kristoffer Hellstrand; Diana Wood; John M Kirkwood; Kurt Gehlsen; Peter Naredi
Results from a randomized phase III study comparing combined treatment with histamine dihydrochloride plus interleukin-2 versus interleukin-2 alone in patients with metastatic melanoma.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2002;20(1):125-33.
2001: Johan Bylund; Thierry Christophe; T Cristophe; François Boulay; A Romero; Kristoffer Hellstrand; Claes Dahlgren
A proinflammatory peptide from Helicobacter pylori activates monocytes to induce lymphocyte dysfunction and apoptosis.
The Journal of clinical investigation 2001;108(8):1221-8.
2001: Asa Betten; Claes Dahlgren; Svante Hermodsson; Kristoffer Hellstrand
Serotonin protects NK cells against oxidatively induced functional inhibition and apoptosis.
Journal of leukocyte biology 2001;70(1):65-72.
2000: Kristoffer Hellstrand; Mats Brune; Claes Dahlgren; Markus Hansson; Svante Hermodsson; Per Lindnér; Ulf-Henrik Mellqvist; Peter Naredi
Alleviating oxidative stress in cancer immunotherapy: a role for histamine?
Medical oncology (Northwood, London, England) 2000;17(4):258-69.
2000: Ulf-Henrik Mellqvist; M Hansson; Mats Brune; Claes Dahlgren; Svante Hermodsson; Kristoffer Hellstrand
Natural killer cell dysfunction and apoptosis induced by chronic myelogenous leukemia cells: role of reactive oxygen species and regulation by histamine.
Blood 2000;96(5):1961-8.
2000: Ingibjörg H Jonsdottir; Kristoffer Hellstrand; P Thorén; P Hoffmann
Enhancement of natural immunity seen after voluntary exercise in rats. Role of central opioid receptors.
Life sciences 2000;66(13):1231-9.
2000: Kristoffer Hellstrand; Markus Hansson; Svante Hermodsson
Adjuvant histamine in cancer immunotherapy.
Seminars in cancer biology 2000;10(1):29-39.
2000: Kristoffer Hellstrand; Mats Brune; Peter Naredi; Ulf-Henrik Mellqvist; Markus Hansson; Kurt Gehlsen; Svante Hermodsson
Histamine: a novel approach to cancer immunotherapy.
Cancer investigation 2000;18(4):347-55.
1999: Markus Hansson; Svante Hermodsson; Mats Brune; Ulf-Henrik Mellqvist; Peter Naredi; Asa Betten; Kurt Gehlsen; Kristoffer Hellstrand
Histamine protects T cells and natural killer cells against oxidative stress.
Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research 1999;19(10):1135-44.
1999: Magnus Rizell; Peter Naredi; Per Lindnér; Kristoffer Hellstrand; Per-Anders Jansson
Validation of the internal reference technique for microdialysis measurements of interstitial histamine in the rat.
Life sciences 1999;65(17):1765-71.
1998: Kristoffer Hellstrand; Svante Hermodsson; Peter Naredi; Ulf-Henrik Mellqvist; Mats Brune
Histamine and cytokine therapy.
Acta oncologica (Stockholm, Sweden) 1998;37(4):347-53.
1998: Kristoffer Hellstrand; Mats Brune; Ulf-Henrik Mellqvist; Gunnar Norkrans; PA Lundberg; Svante Hermodsson; Rune Wejstål
Histamine and the response to IFN-alpha in chronic hepatitis C.
Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research 1998;18(1):21-2.
1997: Kristoffer Hellstrand; Ulf-Henrik Mellqvist; E Wallhult; Jan Carneskog; Eva Kimby; Fredrik Celsing; M Brune
Histamine and interleukin-2 in acute myelogenous leukemia.
Leukemia & lymphoma 1997;27(5-6):429-38.
1997: E Cvetkovska; Alexzander Asea; Kristoffer Hellstrand; Staffan Edström
Tumor suppressive action of indomethacin is NK-cell-independent.
Anticancer research 1997;17(5A):3403-7.
1997: Ingibjörg H Jonsdottir; C Johansson; Alexzander Asea; P Johansson; Kristoffer Hellstrand; P Thorén; P Hoffmann
Duration and mechanisms of the increased natural cytotoxicity seen after chronic voluntary exercise in rats.
Acta physiologica Scandinavica 1997;160(4):333-9.
1997: Kristoffer Hellstrand; Svante Hermodsson; M Brune; Peter Naredi; Jan Carneskog; Ulf-Henrik Mellqvist
Histamine in cancer immunotherapy.
Scandinavian journal of clinical and laboratory investigation 1997;57(3):193-202.
1996: Mats Brune; M Hansson; Ulf-Henrik Mellqvist; Svante Hermodsson; Kristoffer Hellstrand
NK cell-mediated killing of AML blasts: role of histamine, monocytes and reactive oxygen metabolites.
European journal of haematology 1996;57(4):312-9.
1996: Ingibjörg H Jonsdottir; C Johansson; Alexzander Asea; Kristoffer Hellstrand; P Hoffmann
Acute mental stress but not enforced muscle activity transiently increases natural cytotoxicity in spontaneously hypertensive rats.
Acta physiologica Scandinavica 1996;157(4):443-9.
1996: M Hansson; Alexzander Asea; Svante Hermodsson; Kristoffer Hellstrand
Histaminergic regulation of NK-cells: protection against monocyte-induced apoptosis.
Scandinavian journal of immunology 1996;44(2):193-6.
1996: Alexzander Asea; M Hansson; Cecil Czerkinsky; T Houze; Svante Hermodsson; O Strannegård; Kristoffer Hellstrand
Histaminergic regulation of interferon-gamma (IFN-gamma) production by human natural killer (NK) cells.
Clinical and experimental immunology 1996;105(2):376-82.
1996: Ingibjörg H Jonsdottir; Alexzander Asea; P Hoffmann; U I Dahlgren; B Andersson; Kristoffer Hellstrand; P Thorén
Voluntary chronic exercise augments in vivo natural immunity in rats.
Journal of applied physiology (Bethesda, Md. : 1985) 1996;80(5):1799-803.
1996: Ingibjörg H Jonsdottir; C Johansson; Alexzander Asea; Kristoffer Hellstrand; P Thorén; P Hoffmann
Chronic intracerebroventricular administration of beta-endorphin augments natural killer cell cytotoxicity in rats.
Regulatory peptides 1996;62(2-3):113-8.
1996: Kristoffer Hellstrand; Mats Brune; Ulf-Henrik Mellqvist; Peter Naredi
Histamine, cimetidine and colorectal cancer.
Nature medicine 1996;2(4):364-5.
1996: Ingibjörg H Jonsdottir; Alexzander Asea; P Hoffmann; Kristoffer Hellstrand; P Thorén
Natural immunity and chronic exercise in rats. The involvement of the spleen and the splenic nerves.
Life sciences 1996;58(23):2137-46.
1996: M Hansson; Alexzander Asea; U Ersson; Svante Hermodsson; Kristoffer Hellstrand
Induction of apoptosis in NK cells by monocyte-derived reactive oxygen metabolites.
Journal of immunology (Baltimore, Md. : 1950) 1996;156(1):42-7.
1996: Alexzander Asea; Svante Hermodsson; Kristoffer Hellstrand
Histaminergic regulation of natural killer cell-mediated clearance of tumour cells in mice.
Scandinavian journal of immunology 1996;43(1):9-15.
1995: Kristoffer Hellstrand; Alexzander Asea; Svante Hermodsson
Role of histamine in natural killer cell-dependent protection against herpes simplex virus type 2 infection in mice.
Clinical and diagnostic laboratory immunology 1995;2(3):277-80.
1995: Bo Wängberg; Håkan Ahlman; Ulf Tylen; Ola Nilsson; Svante Hermodsson; Kristoffer Hellstrand
Accumulation of natural killer cells after hepatic artery embolisation in the midgut carcinoid syndrome.
British journal of cancer 1995;71(3):617-8.
1994: Kristoffer Hellstrand; Peter Naredi; P Lindner; Kent Lundholm; C M Rudenstam; Svante Hermodsson; M Asztély; Larsolof Hafström
Histamine in immunotherapy of advanced melanoma: a pilot study.
Cancer immunology, immunotherapy : CII 1994;39(6):416-9.
1994: Kristoffer Hellstrand; Alexzander Asea; Claes Dahlgren; Svante Hermodsson
Histaminergic regulation of NK cells. Role of monocyte-derived reactive oxygen metabolites.
Journal of immunology (Baltimore, Md. : 1950) 1994;153(11):4940-7.
1994: Kristoffer Hellstrand; Alexzander Asea; Svante Hermodsson
Histaminergic regulation of antibody-dependent cellular cytotoxicity of granulocytes, monocytes, and natural killer cells.
Journal of leukocyte biology 1994;55(3):392-7.
1993: Kristoffer Hellstrand; Cecil Czerkinsky; Anne Ricksten; B Jansson; Alexzander Asea; H Kylefjord; Svante Hermodsson
Role of serotonin in the regulation of interferon-gamma production by human natural killer cells.
Journal of interferon research 1993;13(1):33-8.
1993: Sven-Olof Olofsson; I Sjöblom; Kristoffer Hellstrand; D Shugar; C Clairmont; C Hirschberg
5-Propyl-2-deoxyuridine induced interference with glycosylation in herpes simplex virus infected cells. Nature of PdU-induced modifications of N-linked glycans.
Archives of virology 1993;128(3-4):241-56.
1993: Kristoffer Hellstrand; Svante Hermodsson
Serotonergic 5-HT1A receptors regulate a cell contact-mediated interaction between natural killer cells and monocytes.
Scandinavian journal of immunology 1993;37(1):7-18.
1992: Kristoffer Hellstrand; H Kylefjord; Alexzander Asea; Svante Hermodsson
Regulation of the natural killer cell response to interferon-alpha by biogenic amines.
Journal of interferon research 1992;12(3):199-206.
1991: Kristoffer Hellstrand; Svante Hermodsson
Cell-to-cell mediated inhibition of natural killer cell proliferation by monocytes and its regulation by histamine H2-receptors.
Scandinavian journal of immunology 1991;34(6):741-52.
1991: Kristoffer Hellstrand; B Kjellson; Svante Hermodsson
Monocyte-induced down-modulation of CD16 and CD56 antigens on human natural killer cells and its regulation by histamine H2-receptors.
Cellular immunology 1991;138(1):44-54.
1990: Kristoffer Hellstrand; Alexzander Asea; Svante Hermodsson
Role of histamine in natural killer cell-mediated resistance against tumor cells.
Journal of immunology (Baltimore, Md. : 1950) 1990;145(12):4365-70.
1990: Kristoffer Hellstrand; Svante Hermodsson
Monocyte-mediated suppression of IL-2-induced NK-cell activation. Regulation by 5-HT1A-type serotonin receptors.
Scandinavian journal of immunology 1990;32(2):183-92.
1990: Kristoffer Hellstrand; Svante Hermodsson
A cell-to-cell mediated interaction involving monocytes and non-T/CD16+ natural killer (NK) cells is required for histamine H2-receptor-mediated NK-cell activation.
Scandinavian journal of immunology 1990;31(5):631-44.
1990: Kristoffer Hellstrand; Svante Hermodsson
Enhancement of human natural killer cell cytotoxicity by serotonin: role of non-T/CD16+ NK cells, accessory monocytes, and 5-HT1A receptors.
Cellular immunology 1990;127(1):199-214.
1990: Kristoffer Hellstrand; Svante Hermodsson
Synergistic activation of human natural killer cell cytotoxicity by histamine and interleukin-2.
International archives of allergy and applied immunology 1990;92(4):379-89.
1989: Kristoffer Hellstrand; Svante Hermodsson
Interleukin-2 can induce suppression of human natural killer cell cytotoxicity.
Clinical and experimental immunology 1989;77(3):410-6.
1989: Kristoffer Hellstrand; Svante Hermodsson
An immunopharmacological analysis of adrenaline-induced suppression of human natural killer cell cytotoxicity.
International archives of allergy and applied immunology 1989;89(4):334-41.
1987: Kristoffer Hellstrand; Svante Hermodsson
Role of serotonin in the regulation of human natural killer cell cytotoxicity.
Journal of immunology (Baltimore, Md. : 1950) 1987;139(3):869-75.
1987: Kristoffer Hellstrand; Svante Hermodsson
Differential effects of histamine receptor antagonists on human natural killer cell activity.
International archives of allergy and applied immunology 1987;84(3):247-55.
1987: O Strannegård; J Björkander; Kristoffer Hellstrand; A Pacsa; Svante Hermodsson; Lars A Hanson
Interferon and beta 2-microglobulin in patients with common variable immunodeficiency or selective IgA deficiency.
International archives of allergy and applied immunology 1987;84(3):217-22.
1986: Tomas Bergström; G Biberfeldt; B Böttiger; C Håkansson; Kristoffer Hellstrand; Svante Hermodsson; Gunnar Norkrans; O Strannegård; K Thorén
Impaired production of alpha and gamma interferon in asymptomatic homosexual males.
European journal of clinical microbiology 1986;5(5):523-9.
1986: Kristoffer Hellstrand; Svante Hermodsson
Histamine H2-receptor-mediated regulation of human natural killer cell activity.
Journal of immunology (Baltimore, Md. : 1950) 1986;137(2):656-60.
1985: Kristoffer Hellstrand; Svante Hermodsson; O Strannegård
Evidence for a beta-adrenoceptor-mediated regulation of human natural killer cells.
Journal of immunology (Baltimore, Md. : 1950) 1985;134(6):4095-9.